We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.

Today’s episode we will cover 2025 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

Today’s episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options.

This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.

This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome.

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.

This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship! We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.

This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer. We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.

This week’s episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease.

This week’s episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others.

This week’s episode will be focusing on exciting data to come at the ASCO Annual Meeting 2025 starting with the plenary sessions, then a special focus on the GU abstracts, including prostate CA, renal cell carcinoma, bladder CA, and a quick shout-out for some of the medical education sessions.

This week’s episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.

This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 2 discusses conditioning regimens, graft-vs-host disease, toxicities, and Dr. Auletta's career path.

This week’s episode will be focusing on Hematopoietic Stem Cell Transplant. We welcome our guest Dr. Jeff Auletta, Senior Vice President, National Marrow Donor Program, and Chief Scientific Director,Center for International Blood and Marrow Transplant Research. Part 1 discusses important basics including what a transplant is, types of transplant & associated risks, types of donors, how to find a donor, and barriers/inequities of finding a donor.

This week’s episode is part 2 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of non-seminoma last year, released 4/22/2024, but today, we will be repeating a quick overview of the staging and management for initial treatment of non-seminoma as well as refractory disease.

This week’s episode is part 1 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of testicular CA last year, released in April 2024, but today, we will be repeating a quick overview of risk factors and staging for testicular cancer, as well as the management of seminoma.

This week’s episode will be focusing on an update of CLL. We will go over important details on the presentation, diagnosis, prognostic factors, and treatment options for initial and refractory disease, as well as key toxicities.

We are so excited to welcome back Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at MSK in NYC, and co-host of the podcast 'The Good News About Cancer'. This episode will cover metastatic prostate cancer including board review pearls & key toxicities of treatments, upcoming exciting research in PCa, and advice for trainees/early career faculty.

We are so excited to welcome Dr. Charles (Chuck) Ryan for our 2025 prostate cancer updates. Dr. Ryan is an internationally recognized GU oncologist and prostate cancer expert, seeing patients at Memorial Sloan Kettering in NYC. This episode will cover localized prostate cancer, risk factors, staging, role of PET PSMA, risk stratification, treatments, as well as introduce biochemical recurrence.

Today’s episode is focusing on what you need to know regarding metastatic colon cancer. This will include the need to know about molecular studies, treatment, and surgery for oligometastatic disease. There has been three breakthroughs since we last covered this topic in the treatment of metastatic CRC based on molecular findings that we will go over today.